HPV, p16 und die TNM-Klassifikation von Oropharynxkarzinomen

Weltweit weisen zwischen 30 und 80 % der Oropharynxkarzinome eine HPV-Infektion der Tumorzellen auf. HPV-assoziierte Oropharynxkarzinome unterscheiden sich von HPV-negativen Fällen durch einen günstigeren Verlauf. Diesem Umstand versucht die achte Auflage der TNM Klassifikation maligner Tumoren Rechnung zu tragen. Der Nachweis der HPV-Assoziation ist daher zum essentiellen Bestandteil der histopathologischen Diagnostik bei Oropharynxkarzinomen geworden.

• Literatur

• 1 Brandsma JL, Abramson AL. Association of papillomavirus with cancers of the head and neck. Arch Otolaryngol Head Neck Surg 1989; 115: 621-625
• 2 Niedobitek G, Pitteroff S, Herbst H. et al. Detection of human papillomavirus type 16 DNA in carcinomas of the palatine tonsil. J Clin Pathol 1990; 43: 918-921
• 3 Salazar CR, Smith RV, Garg MK. et al. Human papillomavirus-associated head and neck squamous cell carcinoma survival: a comparison by tumor site and initial treatment. Head Neck Pathol 2014; 8: 77-87
• 4 Hauck F, Oliveira-Silva M, Dreyer JH. et al. Prevalence of HPV infection in head and neck carcinomas shows geographical variability: a comparative study from Brazil and Germany. Virchows Arch 2015; 466: 685-693
• 5 Ang KK, Harris J, Wheeler R. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35
• 6 Brierley JD, Gospodarowicz MK, Wittekind C. (eds). TNM classification of malignant tumors. Wiley-Blackwell; 2016
• 7 Egawa N, Egawa K, Griffin H. et al. Human papillomaviruses, epithelial tropisms, and the development of neoplasia. Viruses 2015; 7: 3863-3890
• 8 Dreyer JH, Hauck F, Oliveira-Silva M. et al. Detection of HPV infection in head and neck squamous cell carcinoma: a practical proposal. Virchows Arch 2013; 462: 381-389
• 9 Dreyer JH, Hauck F, Barros MH. et al. pRb and cyclinD1 complement p16 as immunohistochemical surrogate Markers of HPV infection in head and neck cancer. Appl Immunohistochem Mol Morphol. 2015 Dec 9 [Epub ahead of print]
• 10 Jouhi L, Hagström J, Atula T. et al. Is p16 an adequate surrogate for human papillomavirus status determination?. Curr Opin Otolaryngol Head Neck Surg 2017; 25: 108-112
• 11 Lewis Jr JS, Thorstad WL, Chernock RD. et al. p16 positive oropharyngeal squamous cell carcinoma:an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol 2010; 34: 1088-1096
• 12 Rietbergen MM, Snijders PJ, Beekzada D. et al. Molecular characterization of p16-immunopositive but HPV DNA-negative oropharyngeal carcinomas. Int J Cancer 2014; 134: 2366-2372
• 13 Dietz A, Wichmann G, Wiegand S. Should we de-escalate the treatment for HPV-positive tumors?. Recent Results Cancer Res 2017; 206: 173-181
• 14 O'Sullivan B, Huang SH, Su J. et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol 2016; 17: 440-451